Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
Omega 3 oil 18 EPA/12 DHA is highly demanded worldwide for its multiple benefits for human and animal health
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Subscribe To Our Newsletter & Stay Updated